[N:1]1[CH:6]=[CH:5][CH:4]=[CH:3][C:2]=1[CH2:7][C:8]([O:10]C)=O.[F:12][C:13]([F:34])([F:33])[C:14]1[CH:15]=[C:16]([S:20]([CH2:23][CH2:24][S:25][C:26]2[C:31]([NH2:32])=[CH:30][CH:29]=[CH:28][N:27]=2)(=[O:22])=[O:21])[CH:17]=[CH:18][CH:19]=1.CCCCCC>C1(C)C(C)=CC=CC=1.CCOC(C)=O>[N:1]1[CH:6]=[CH:5][CH:4]=[CH:3][C:2]=1[CH2:7][C:8]([NH:32][C:31]1[C:26]([S:25][CH2:24][CH2:23][S:20]([C:16]2[CH:17]=[CH:18][CH:19]=[C:14]([C:13]([F:33])([F:34])[F:12])[CH:15]=2)(=[O:22])=[O:21])=[N:27][CH:28]=[CH:29][CH:30]=1)=[O:10]302 mg (2.0 mmol) methyl 2-(pyridin-2-yl)acetate were added to a solution of 362 mg (1.0 mmol) [2-[2-[[3-(trifluoromethyl)phenyl]sulfonyl]-ethylsulfanyl]-pyridin-3-yl]amine (VPF-001) in xylene (4 ml) and the mixture was then heated for 7 h at 150° C. After cooling to RT the mixture was diluted with EtOAc and the phases were separated. The organic phase was washed with water and brine, dried over Na2SO4, filtered and concentrated to small volume under vacuum. Column chromatography (hexane/EE 6:4) of the residue yielded 154 mg (0.32 mmol, 32%) 2-pyridin-2-yl-N-[2-[2-[[3-(trifluoromethyl)phenyl]sulfonyl]-ethylsulfanyl]-pyridin-3-yl]acetamide. MS: m/z 482.1 [M+H]+.